Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MelCure SA
• Collaborators: California Institute of Technology; Universitaire Ziekenhuizen Leuven; University of Bern
• Treatments: BQ 788

Criteria

Inclusion Criteria:

• Written Informed consent

• Histologically confirmed melanoma

• Disease stage III or IV

• At least 2 injectable and surgically removable cutaneous metastasis

• Age > 18 years

• Clinically stable medical condition

Exclusion Criteria:

• Primary ocular melanoma

• Symptomatic intracranial melanoma

• History of severe neurological, cardiovascular, renal, hepatic, endocrinological, respiratory, bone marrow, autoimmune or infectious (HIV) disease

• Pregnancy or lactation